ASC1 Antibody - BSA Free

Immunohistochemistry-Paraffin: ASC1 Antibody - BSA Free [NBP1-89656]

Staining of human colon shows cytoplasmic positivity in glandular cells.

Western Blot: ASC1 Antibody - BSA Free [NBP1-89656]

Lane 1: NIH-3T3 cell lysate (Mouse embryonic fibroblast cells)
Lane 2: NBT-II cell lysate (Rat Wistar bladder tumour cells)

Western Blot: ASC1 Antibody - BSA Free [NBP1-89656] -

Liraglutide inhibits glucolipotoxicity-induced NF kappaB pro-inflammatory responses. (a) Western blots showed that 0.1 μM Liraglutide inhibits glucolipotoxicity-induced NF kappaB p65 subunit phosphorylation at Ser536 and prevents I kappaB alpha degradation at 24 h. (b) Double fluorescence staining revealed that Liraglutide inhibits the entry of the NF kappaB p65 subunit into the nucleus under glucolipotoxicity. Scale bar: 20 μm. (c) qPCR results demonstrated that under glucolipotoxicity, liraglutide significantly reduces the mRNA expression levels of the IL-1 beta, TNF alpha, and MCP-1 pro-inflammatory cytokines, and simultaneously restores the IL-4, IL-10, and IGF-1 anti-inflammatory cytokines. (d) Western blot analysis of NLRP3, ASC, and cleaved-caspase-1 confirmed that Liraglutide suppresses glucolipotoxicity-induced inflammasome activation. Arrows indicate nuclear p65 immunolabeling. All values are presented as the mean +/- SEM. Significant difference was determined using multiple comparisons of Dunnett’s posthoc test for ** p < 0.01 compared to the Control group; ## p < 0.01 compared to the HG+HF group. Image collected and cropped by CiteAb from the following open publication (https://pubmed.ncbi.nlm.nih.gov/36291547), licensed under a CC-BY license. Not internally tested by Novus Biologicals.